Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

✍ Scribed by Ascierto, P. A.; Minor, D.; Ribas, A.; Lebbe, C.; O'Hagan, A.; Arya, N.; Guckert, M.; Schadendorf, D.; Kefford, R. F.; Grob, J.-J.; Hamid, O.; Amaravadi, R.; Simeone, E.; Wilhelm, T.; Kim, K. B.; Long, G. V.; Martin, A.-M.; Mazumdar, J.; Goodman, V. L.; Trefzer, U.

• Book ID: 121467429
• Publisher: American Society of Clinical Oncology
• Year: 2013
• Tongue: English
• Weight: 182 KB
• Volume: 31
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2013.49.8691